ADC Arms Race Accelerates: Lilly and Gilead Double Down on Next-Generation Oncology Platforms. Acquisitions of CrossBridge and Tubulis highlight how antibody-drug conjugates are becoming a central pillar of oncology pipeline strategy.

Strategic Reallocation in Action: Takeda, Daiichi Sankyo, and Shionogi refocus for Growth and Market Access. Portfolio exits, capital shifts, and U.S. manufacturing expansion highlight how companies are actively adjusting strategic levers.

From oral biologics to next-generation RNA therapies, companies are investing heavily in platforms that redefine how medicines are delivered and where they act.

Korsana Biosciences raised $175 million to develop next-generation Alzheimer’s antibodies. Its lead candidate uses transferrin receptor targeting to cross the blood-brain barrier. The company plans to enter clinical trials in 2027. Several competitors are pursuing similar delivery strategies.

The week we've had Eyes on the Ocular Therapeutix phase 3 SOL-1 data showing superiority over Eylea in wet AMD. The trial showed improved visual acuity preservation, The program could introduce the first tyrosine kinase inhibitor therapy for wet AMD however, investors reacted cautiously to the news.

Last week we had Eyes On more M&A counter offers + the success of M&A as Kura Oncology's Komzifti gets approved in the US (partner Kyowa Kirin). What caught you eye in BioPharma News lately?

The newest pharmaceutical behemoths to reach MFN pricing agreements with the White House are Eli Lilly and Novo Nordisk, who have agreed to sell their weight-loss medications to Americans at reduced costs.

We're keeping Eyes On Diabesity. With new approvals, data on the horizon, and M&A to bolster pipelines, it seems like there's something new everyday. Here we cover new MACE indications and the Metsera bidding war. What were you watching?

Lately, we've kept our Eyes On Sarepta Therapeutics and their discussions with the US FDA regarding their gene therapy Product Elevidys, their pipeline platform. All of this, plus the management shuffles at the FDA itself, has created quite a stir in the industry.

This month we've had Eyes On The BBB and potential timing and impact on the BioPharma sector. This is a dynamic area, with many different news bytes daily, let us know what you'v e seen and what sources you are following.

This week we've kept Eyes On the MFN and Tariff news, plus the Moderna x HHS Break-up and the Lilly x SiteOne Deal. The BioPharma Marketplace is in flux and we're watching to see how everyone is adapting and re-aligning their strategies.

We've been keeping Eyes On Regulatory news, both in the US and Europe. We're sharing a few of the updates from the past few weeks on approval timing, staffing changes, clinical results, international company coalitions, and more.

23andMe files for Chapter 11 bankruptcy and seeks a court-managed sale, co-founder and CEO Anne Wojcicki will step down

For ten titans of industry in 2025, the U.S. patent runway is coming to a close.

This month we've been watching how different companies are managing their pipelines, and keeping Eyes On other hot news topics.

We've had Eye's On the JP Morgan Healthcare Conference, Lifesciences 2024 restructuring stats, and some new drug development partnerships.

Check out the final listings of FDA NDA and BLA approvals for 2024.

We've highlighted a few firms: Lilly, AbbVie, Pfizer, Novo Nordisk, BMS, Roche, Novartis, Merck, AstraZeneca, GSK, Viatris, Teva, and Amgen.

Eye's on the Amgen data releases for gMG & Atopic Dermatitis, the BMS approval of Cobenfy for schizophrenia, and Pfizer's Oxbryta recall...

This month, we've had Eyes on investment trends, strategic restructuring, and FDA decisions. Fall seems to be gearing up, and we can't wait